(Reuters) – Germany has signed a contract with CureVac and its British partner GlaxoSmithKline for supply of domestically produced mRNA vaccines until 2029 in case of public health emergencies, the German biotech firm on Monday.
The contract allows for the production of up to 80 million doses at short notice, CureVac said, and follows the German government’s plans last month to spend nearly 3 billion euros ($3.3 billion) to ensure COVID-19 vaccine makers had enough capacity for local supply.
($1 = 0.9173 euros)
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Shounak Dasgupta)
